NCT06693687

A Study of the ApricityCare Program for Early Detection and Management of Treatment-Related Adverse Events in Patients With Cancer

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 425 (estimated)
• Sponsor: M.D. Anderson Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the rate of therapy discontinuation due to toxicity (side effects) among participants with cancer using ApricityCare. Investigators want to learn if identification of early clinical signs of irAEs with timely treatment can prevent severity progression and reduce treatment discontinuation.

Detailed description

Primary Objective • To determine the rate of therapy discontinuation due to toxicity among patients using ApricityCare. Secondary Objectives • To evaluate time the ease and experience of patient use of ApricityCare (i.e., patient engagement) in reporting symptoms during their systemic cancer treatments. Furthermore, the frequency of patient symptom reporting via check-in to ApricityCare will be evaluated, as will the time taken to respond and engage patients after they report toxicity or other adverse events via ApricityCare.

Conditions

• Metastatic Cancer

Interventions

Type	Name	Description
BEHAVIORAL	Metastatic Cancer	Participants will be asked to to take part in a research study because you have metastatic cancer (meaning that your cancer has spread to other parts of the body) and will be starting systemic therapy.

Timeline

• Start date: 2024-12-18
• Primary completion: 2027-11-01
• Completion: 2027-11-01
• First posted: 2024-11-18
• Last updated: 2025-12-30

Locations

1 site across 1 country: United States